Propanc Biopharma reports FY23 update, uplists to Nasdaq.

• Propanc Biopharma announced FY-end update • Focused on developing treatments for recurring and metastatic cancer • Filed annual 10-K report with SEC on Sept 29, 2025 • Completed IPO and uplisting to Nasdaq on Aug 14, 2025 • Significant changes in financial position during the year • Supporting future operational and research activities • CEO James Nathanielsz stated the company is focused on advancing lead therapeutic candidate • Building intellectual property portfolio with milestones in 2025 and 2026 • Engaged in collaborative efforts • Expected to support future operational and research activities

Propanc Biopharma, Inc. (Nasdaq: PPCB) has released its fiscal year-end update following the filing of its annual 10-K report with the Securities and Exchange Commission on September 29, 2025. The company, which specializes in developing treatments for recurring and metastatic cancer, has reported significant changes in its financial position during the year. These changes have enabled Propanc to complete an initial public offering (IPO) and uplisting to Nasdaq on August 14, 2025 Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy^[1].

The IPO involved an underwriting agreement with D Boral Capital, resulting in the offering of 1,000,000 common shares, which generated gross proceeds of $4 million. This financial boost is expected to support future operational and research activities, including the advancement of the company's lead therapeutic candidate and the building of its intellectual property portfolio. CEO James Nathanielsz stated that the company anticipates achieving various development milestones by the end of 2025 and throughout 2026 Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy^[1].

Propanc's novel approach to cancer treatment involves using pancreatic proenzymes to target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian, and colorectal cancers. The company's proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, with a particular focus on enzymes secreted by the pancreas as the body's primary defense against cancer Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy^[1].

In addition to its internal advancements, Propanc is actively engaged in collaborative efforts with regards to its clinical pipeline. The company aims to create a $100 million or greater digital asset treasury over the next twelve months, joining over 200 public companies that hold digital assets in their treasuries. These digital assets, primarily Bitcoin and Ethereum, are increasingly being viewed as strategic corporate assets Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy^[1].

While Propanc's forward-looking statements include expectations regarding its market position and product development, investors should be aware of the risks and uncertainties associated with such statements. These risks include market conditions and other factors described in the company's filings with the SEC Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy^[1].